---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-083326"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2026-07-14T11:00:58+00:00"
generated_at: "2026-07-14T11:05:10.190447+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# NextCure to reverse merge with Avere; Avere holders get ~98% of combined co; $320M PIPE

## Summary
- NextCure (NXTC) to acquire Avere Therapeutics via reverse merger; Avere stockholders will own ~98.11% of combined company; NextCure stockholders ~1.89%.
- Concurrent $320M private placement from institutional investors into Avere; condition of at least $150M proceeds at close.
- NextCure to reduce workforce by substantial majority; expects ~$1.9M one-time charges in Q3 2026.
- NextCure halts new patient enrollment in SIM0505 ADC study in US; opts out of cost-sharing for LNCB74 ADC; not due to safety/efficacy.
- Pre-merger NextCure stockholders to receive CVRs entitling them to 90% of proceeds from future monetization of legacy assets.

## SEC filing metadata
- accession: 0001104659-26-083326
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2026-07-14T11:00:58+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 2.05, 5.01, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/0001104659-26-083326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/tm2620428d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-083326
- JSON: https://secwatch.observer/filing/0001104659-26-083326.json
- Plain text: https://secwatch.observer/filing/0001104659-26-083326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.